MX2024004150A - Metodos y productos para tratar sujetos con trastornos del espectro autista. - Google Patents

Metodos y productos para tratar sujetos con trastornos del espectro autista.

Info

Publication number
MX2024004150A
MX2024004150A MX2024004150A MX2024004150A MX2024004150A MX 2024004150 A MX2024004150 A MX 2024004150A MX 2024004150 A MX2024004150 A MX 2024004150A MX 2024004150 A MX2024004150 A MX 2024004150A MX 2024004150 A MX2024004150 A MX 2024004150A
Authority
MX
Mexico
Prior art keywords
salt
disorder
ticagrelor
products
methods
Prior art date
Application number
MX2024004150A
Other languages
English (en)
Spanish (es)
Inventor
Nava Zisapel
Moshe Laudon
Original Assignee
Neurim Pharmaceuticals 1991 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurim Pharmaceuticals 1991 Ltd filed Critical Neurim Pharmaceuticals 1991 Ltd
Publication of MX2024004150A publication Critical patent/MX2024004150A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2024004150A 2021-10-04 2022-10-03 Metodos y productos para tratar sujetos con trastornos del espectro autista. MX2024004150A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163251935P 2021-10-04 2021-10-04
PCT/IB2022/059429 WO2023057879A1 (en) 2021-10-04 2022-10-03 Methods and products for treating subjects with autism spectrum disorders

Publications (1)

Publication Number Publication Date
MX2024004150A true MX2024004150A (es) 2024-04-22

Family

ID=83688729

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024004150A MX2024004150A (es) 2021-10-04 2022-10-03 Metodos y productos para tratar sujetos con trastornos del espectro autista.

Country Status (16)

Country Link
US (1) US11878016B2 (cg-RX-API-DMAC10.html)
EP (1) EP4412616A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024536341A (cg-RX-API-DMAC10.html)
KR (1) KR20240089377A (cg-RX-API-DMAC10.html)
CN (1) CN118265521A (cg-RX-API-DMAC10.html)
AU (2) AU2022358998B2 (cg-RX-API-DMAC10.html)
CA (1) CA3232273A1 (cg-RX-API-DMAC10.html)
CL (1) CL2024000992A1 (cg-RX-API-DMAC10.html)
CO (1) CO2024005762A2 (cg-RX-API-DMAC10.html)
CR (1) CR20240184A (cg-RX-API-DMAC10.html)
EC (1) ECSP24033949A (cg-RX-API-DMAC10.html)
IL (1) IL311681B2 (cg-RX-API-DMAC10.html)
MX (1) MX2024004150A (cg-RX-API-DMAC10.html)
PE (1) PE20241338A1 (cg-RX-API-DMAC10.html)
TW (1) TW202322821A (cg-RX-API-DMAC10.html)
WO (1) WO2023057879A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025051399A1 (en) * 2023-09-10 2025-03-13 Dafechem Ltd Liquid ticagrelor formulation
WO2025247961A1 (en) * 2024-05-31 2025-12-04 Centre Hospitalier Universitaire Vaudois (C.H.U.V.) Lpa-lpar signaling as a therapeutic target or diagnostic tool for brain diseases

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9233966B2 (en) * 2012-04-05 2016-01-12 Dr. Reddy's Laboratories Limited Preparation of ticagrelor
CN104971042B (zh) 2014-04-04 2018-01-05 中国医学科学院医药生物技术研究所 替格瑞洛口服自微乳组合物
CN104434931A (zh) * 2014-11-06 2015-03-25 南京华威医药科技开发有限公司 含替格瑞洛和阿司匹林的复方口服固体剂及其制备方法
CN105669674A (zh) * 2014-11-21 2016-06-15 重庆圣华曦药业股份有限公司 一种替卡格雷新晶型及其在药物制剂中的应用
RS66536B1 (sr) * 2016-04-21 2025-03-31 Astrazeneca Ab Tablete za oralno raspadanje
CN105943515A (zh) * 2016-06-24 2016-09-21 山东鲁抗医药股份有限公司 一种替格瑞洛口腔崩解片及其制备方法
CN108078944A (zh) * 2016-11-22 2018-05-29 重庆植恩药业有限公司 含有替格瑞洛的固体组合物及其制备方法
TR201617983A2 (tr) * 2016-12-07 2018-06-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Ti̇cagrelorun kati oral farmasöti̇k bi̇leşi̇mleri̇
US10614684B2 (en) * 2017-01-31 2020-04-07 The United States Government As Represented By The Treatment of kidney diseases associated with elevated AVP
EP3700525A4 (en) * 2017-10-27 2021-08-25 Beyond Barriers Therapeutics, Inc. IMPROVED PROVISION OF ANTIOXIDANTS FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES WITH OXIDATIVE STRESS
KR102007731B1 (ko) * 2018-02-12 2019-08-06 충남대학교산학협력단 티카그렐러를 포함하는 자가 미세유화 약물전달시스템 조성물 및 이의 제조방법
CN110876750A (zh) * 2018-09-06 2020-03-13 江苏恒瑞医药股份有限公司 一种含有替格瑞洛或其可药用盐的缓释组合物
CA3179635A1 (en) * 2020-05-29 2021-12-02 Boulder Bioscience Llc Methods for improved endovascular thrombectomy using 3,3'-diindolylmethane

Also Published As

Publication number Publication date
IL311681B1 (en) 2025-10-01
KR20240089377A (ko) 2024-06-20
IL311681B2 (en) 2026-02-01
CR20240184A (es) 2024-07-03
EP4412616A1 (en) 2024-08-14
TW202322821A (zh) 2023-06-16
CO2024005762A2 (es) 2024-05-30
US20230105540A1 (en) 2023-04-06
CA3232273A1 (en) 2023-04-13
CL2024000992A1 (es) 2024-09-13
US11878016B2 (en) 2024-01-23
JP2024536341A (ja) 2024-10-04
CN118265521A (zh) 2024-06-28
PE20241338A1 (es) 2024-07-03
AU2022358998B2 (en) 2025-09-11
AU2025242229A1 (en) 2025-10-23
AU2022358998A1 (en) 2024-04-11
IL311681A (en) 2024-05-01
WO2023057879A1 (en) 2023-04-13
ECSP24033949A (es) 2024-06-28

Similar Documents

Publication Publication Date Title
Gold et al. A major role for the lateral habenula in depressive illness: physiologic and molecular mechanisms
CR20240184A (es) Métodos y productos para tratar sujetos con trastornos del espectro autista
Zhang et al. The clinical correlation between Alzheimer's disease and epilepsy
Van der Lende et al. Cardiac arrhythmias during or after epileptic seizures
Chan et al. BIS-guided anesthesia decreases postoperative delirium and cognitive decline
Cross et al. Napping in older people ‘at risk’of dementia: relationships with depression, cognition, medical burden and sleep quality
Heekeren et al. Mismatch negativity generation in the human 5HT2A agonist and NMDA antagonist model of psychosis
Marshall et al. Transcranial direct current stimulation during sleep improves declarative memory
Sivarao et al. NR2B antagonist CP-101,606 abolishes pitch-mediated deviance detection in awake rats
Soni et al. Levetiracetam for busulfan‐induced seizure prophylaxis in children undergoing hematopoietic stem cell transplantation
Wong et al. Rosiglitazone suppresses in vitro seizures in hippocampal slice by inhibiting presynaptic glutamate release in a model of temporal lobe epilepsy
Sorri et al. Low tumor necrosis factor‐α levels predict symptom reduction during electroconvulsive therapy in major depressive disorder
Fu et al. Impact of autologous mesenchymal stem cell infusion on neuromyelitis optica spectrum Disorder: a pilot, 2‐year observational study
Anagnostou et al. Postural instability during attacks of migraine without aura
Thivakaran et al. Chlorpyrifos-induced delayed myelopathy and pure motor neuropathy: a case report
Bierhansl et al. Neuronal mitochondrial calcium uniporter (MCU) deficiency is neuroprotective in hyperexcitability by modulation of metabolic pathways and ROS balance
Wu et al. Functional reuniens and rhomboid nuclei are required for proper acquisition and expression of cued and contextual fear in trace fear conditioning
Bowman et al. Activity-state dependent reversal of ketamine-induced resting state EEG effects by clozapine and naltrexone in the freely moving rat
Müller et al. Auditory streaming affects the processing of successive deviant and standard sounds
Conde Blanco et al. Hypothalamic hamartomas in adulthood: Clinical spectrum and treatment outcome—A unicenter experience
Elamin et al. Dysfunctional sodium channel kinetics as a novel epilepsy mechanism in chromosome 15q11‐q13 duplication syndrome
Guo et al. A brain signature to differentiate acute and chronic pain in rats
Grados et al. Genetic Findings in Obsessive–Compulsive Disorder Connect to Brain‐Derived Neurotropic Factor and Mammalian Target of Rapamycin Pathways: Implications for Drug Development
Dell'Isola et al. Effect of melatonin on sleep quality and EEG features in childhood epilepsy: a possible non-conventional treatment
Sakakibara et al. Acute psychosis during the postictal period in a patient with idiopathic generalized epilepsy: postictal psychosis or aggravation of schizophrenia? A case report and review of the literature